Novo nordisk achieves primary objectives of onwards 3 and 4 trials with once-weekly insulin icodec demonstrating superior reduction in hba1c vs insulin degludec in onwards 3

BagsvÆrd, denmark , 29 july 2022 – novo nordisk today announced headline results from the onwards 3 and onwards 4 phase 3a trials with once-weekly insulin icodec in adults with type 2 diabetes.

NVO Ratings Summary

NVO Quant Ranking